- Home
- DRCT vs SLGL Comparison
DRCT vs SLGL Comparison
Compare DRCT & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRCT
- SLGL
- Stock Information
- Founded
- DRCT 2018
- SLGL 1997
- Country
- DRCT United States
- SLGL Israel
- Employees
- DRCT N/A
- SLGL N/A
- Industry
- DRCT Computer Software: Programming Data Processing
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- DRCT Technology
- SLGL Health Care
- Exchange
- DRCT Nasdaq
- SLGL Nasdaq
- Market Cap
- DRCT 9.2M
- SLGL 49.4M
- IPO Year
- DRCT 2022
- SLGL 2018
- Fundamental
- Price
- DRCT $0.46
- SLGL $22.79
- Analyst Decision
- DRCT Strong Buy
- SLGL
- Analyst Count
- DRCT 1
- SLGL 0
- Target Price
- DRCT $6.00
- SLGL N/A
- AVG Volume (30 Days)
- DRCT 791.3K
- SLGL 30.5K
- Earning Date
- DRCT 08-05-2025
- SLGL 08-15-2025
- Dividend Yield
- DRCT N/A
- SLGL N/A
- EPS Growth
- DRCT N/A
- SLGL N/A
- EPS
- DRCT N/A
- SLGL N/A
- Revenue
- DRCT $36,459,000.00
- SLGL $23,931,000.00
- Revenue This Year
- DRCT $16.81
- SLGL N/A
- Revenue Next Year
- DRCT $62.96
- SLGL $31.17
- P/E Ratio
- DRCT N/A
- SLGL N/A
- Revenue Growth
- DRCT N/A
- SLGL 264.86
- 52 Week Low
- DRCT $0.38
- SLGL $4.01
- 52 Week High
- DRCT $6.59
- SLGL $26.89
- Technical
- Relative Strength Index (RSI)
- DRCT 48.77
- SLGL 67.74
- Support Level
- DRCT $0.44
- SLGL $21.00
- Resistance Level
- DRCT $0.48
- SLGL $23.91
- Average True Range (ATR)
- DRCT 0.04
- SLGL 2.62
- MACD
- DRCT 0.01
- SLGL 0.27
- Stochastic Oscillator
- DRCT 75.24
- SLGL 66.14
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.